Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity
Nucleic Acid Therapeutics · 01.10.2024 · 34 (5) · 245-256
DOI: 10.1089/nat.2024.0007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 16.10.2024. Verfasst von Kelly E W Carufe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Peptide Nucleic Acids, RNA, Guide, CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Although CRISPR-Cas9 gene therapies have proven to be a powerful tool across many applications, improvements are necessary to increase the specificity of this technology. Cas9 cutting in off-target sites remains an issue that limits CRISPR’s application in human-based therapies. Treatment of autosomal dominant diseases also remains a challenge when mutant alleles differ from the wild-type sequence by only one base pair. Here, we utilize synthetic peptide nucleic acids (PNAs) that bind selected spacer sequences in the guide RNA (gRNA) to increase Cas9 specificity up to 10-fold. We interrogate variations in PNA length, binding position, and degree of homology with the gRNA. Our findings reveal that PNAs bound in the region distal to the protospacer adjacent motif (PAM) site effectively enhance specificity in both on-target/off-target and allele-specific scenarios. In addition, we demonstrate that introducing deliberate mismatches between PNAs bound in the PAM-proximal region of the gRNA can modulate Cas9 activity in an allele-specific manner. These advancements hold promise for addressing current limitations and expanding the therapeutic potential of CRISPR technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Kelly E W Carufe
Förderung
- NCI NIH HHS
- NIAID NIH HHS
Zitieren
APA
Carufe, K. E. W., Economos, N. G., & Glazer, P. M. (2024). Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity. Nucleic Acid Therapeutics, 34(5), 245-256. https://doi.org/10.1089/nat.2024.0007
Vancouver
Carufe KEW, Economos NG, Glazer PM. Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity. Nucleic Acid Therapeutics. 2024;34(5):245-256. doi:10.1089/nat.2024.0007
BibTeX
@article{Carufe2024,
author = {Carufe, Kelly E W and Economos, Nicholas G and Glazer, Peter M},
title = {Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity},
journal = {Nucleic Acid Therapeutics},
year = {2024},
volume = {34},
number = {5},
pages = {245--256},
doi = {10.1089/nat.2024.0007}
}
EUVIMED